Home/Pipeline/Undisclosed Psoriasis Program

Undisclosed Psoriasis Program

Psoriasis

PreclinicalActive

Key Facts

Indication

Psoriasis

Phase

Preclinical

Status

Active

Company

Nepsone

About Nepsone

Nepsone is a private, preclinical biotech founded in 2019 with a novel neuroimmunology hypothesis for dermatological diseases. The company is developing small molecule drugs aimed at correcting autonomic nervous system imbalances, specifically targeting neuropeptide pathways, as a new treatment paradigm for conditions like psoriasis. It is backed by a grant from Iceland's Technology Development Fund (Rannís) and led by a team with expertise in R&D, clinical development, and finance. Nepsone operates in a large, underserved market dominated by biologic therapies, positioning its oral small molecule approach as a potential disruptive alternative.

View full company profile

Therapeutic Areas

Dermatology

Other Psoriasis Drugs

Drug	Company	Phase	Status
Autoimmune psoriasis candidate	Nyrada	Preclinical	Active
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
Laikangqita Monoclonal Antibody	Livzon Pharmaceutical	NDA	Marketing application accepted and granted priority review
CT-P55	Celltrion	Phase 3	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active